|
|
 |
 - Reliable: excellent reproducibility avoids cumbersome and expensive experiment repetitions
- Proven: successfully applied in basic and translational research
|
| Overview |
| CD19 MicroBeads were developed for positive selection or depletion of CD19+ lineage B cells from different cell sources such as human PBMCs, bone marrow, lymphoid tissues, or cell cultures. |
| Details |
Background information
As a B cell lineage marker, the CD19 antigen is expressed from the early pro-B cell stage to the B cell lymphoblast stage, but the expression is down-regulated upon B cell maturation to plasma cells. The CD19 antigen is further expressed on most malignant B cells and on a subset of follicular dendritic cells.
Downstream applications
Isolated CD19+ B cells were used for studies on immunoglobulin production, such as IgE synthesis1, 2 and secretion3, chemotaxis assays4, or mixed lymphocyte reactions. Positively selected CD19+ B cells were also used for molecular studies such as gene expression profiling.5 For the analysis of minimal residual diseases in B cell malignancies, enrichment of B cells increases the sensitivity of detection.6 |
| | |
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| References |
| 1. Aebischer et al. (1994) Eur. J. Immunol. 24: 1908-1913. |
| 2. Stämpfli et al. (1994) Eur. J. Immunol. 24: 2161-2167. |
| 3. Zürcher et al. (1995) Immunol. Lett. 46: 49-57. |
| 4. Schratzberger et al. (1997) J. Immunol. 158: 3895-3901. |
| 5. Klein et al. (2001) J. Exp. Med. 194: 1625-1638. |
| 6. Pugh et al. (1998) J. Hematotherapy 7: 159-168. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
